NEOG NEOGEN CORP

FY2025 10-K
Filed: Jul 30, 2025
Health Care
In Vitro & In Vivo Diagnostic SubstancesSEC EDGAR

NEOGEN CORP (NEOG) filed its fiscal year 2025 10-K annual report with the SEC on Jul 30, 2025. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.

AI Filing Analysis
FY2025 10-K

Business Overview

  • Core business model: Develops, manufactures, and markets diagnostic test kits and complementary products for food and animal safety globally
  • New emphasis: Completion of 3M Food Safety Division acquisition Sept 2022, now a wholly owned subsidiary, expanding Food Safety segment portfolio
+3 more insights

Management Discussion & Analysis

  • Revenue $894.7M, down 3% YoY from $924.2M, decline driven by $24.3M FX headwind and $3.9M discontinued product lines
  • Gross margin 47.1% vs 50.2% YoY, decrease due to lower volume, higher manufacturing costs, inventory write-offs, tariffs, and $4.4M restructuring charges
+5 more insights

Risk Factors

  • Foreign exchange risk reducing revenue by $44.9M from 10% USD depreciation, impacting 50.2% of international revenues in fiscal year 2025
  • Interest rate risk with 38.9% of total debt at variable rates, causing $2.6M earnings loss from 75 basis point rate increase
+3 more insights

Financial Summary
XBRL

Revenue

$895M

Net Income

-$1.1B

Gross Margin

47.1%

Operating Margin

-118.6%

Net Margin

-122.1%

ROE

-52.7%

Total Assets

$3.4B

EPS (Diluted)

$-5.03

Operating Cash Flow

$58M

Source: XBRL data from NEOGEN CORP FY2025 10-K filing on SEC EDGAR. All figures in USD.

Get deeper insights on NEOGEN CORP

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.

Try Pro free for 1 month!

Enter SX-8KKYTN at checkout

Limited spots available